THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 119 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $600,900 | -84.5% | 58,058 | -83.7% | 0.00% | -81.8% |
| Q1 2023 | $3,872,007 | -64.2% | 356,867 | -62.9% | 0.01% | -67.6% |
| Q4 2022 | $10,802,908 | +63.2% | 962,826 | +47.5% | 0.03% | +54.5% |
| Q3 2022 | $6,620,000 | +363.9% | 652,870 | +337.5% | 0.02% | +450.0% |
| Q1 2022 | $1,427,000 | +268.7% | 149,240 | +325.6% | 0.00% | +300.0% |
| Q4 2021 | $387,000 | -53.7% | 35,066 | -14.4% | 0.00% | -50.0% |
| Q1 2021 | $836,000 | +43.2% | 40,962 | +3.7% | 0.00% | 0.0% |
| Q3 2020 | $584,000 | -83.8% | 39,519 | -77.0% | 0.00% | -88.9% |
| Q2 2020 | $3,611,000 | +606.7% | 172,050 | +998.9% | 0.02% | +1700.0% |
| Q3 2018 | $511,000 | -40.5% | 15,656 | -41.9% | 0.00% | -66.7% |
| Q4 2016 | $859,000 | +123.1% | 26,931 | +153.3% | 0.00% | +200.0% |
| Q3 2016 | $385,000 | -44.8% | 10,632 | -77.3% | 0.00% | -75.0% |
| Q4 2014 | $698,000 | – | 46,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Woodford Investment Management Ltd | 11,213,879 | $254,331,000 | 30.84% |
| Cormorant Asset Management, LP | 1,300,000 | $29,484,000 | 2.18% |
| Baupost Group | 9,309,168 | $211,132,000 | 1.85% |
| SENZAR ASSET MANAGEMENT, LLC | 27,397 | $621,000 | 1.79% |
| ARMISTICE CAPITAL, LLC | 1,180,000 | $26,762,000 | 1.75% |
| Old West Investment Management, LLC | 111,101 | $2,519,000 | 1.27% |
| Chescapmanager LLC | 403,321 | $9,147,000 | 1.06% |
| Virtus ETF Advisers LLC | 30,055 | $682,000 | 0.60% |
| Rock Springs Capital Management LP | 652,600 | $14,801,000 | 0.57% |
| Foundation Asset Management, LP | 27,154 | $616,000 | 0.53% |